Will AbbVie's Oncology Segment Support Top-line Growth in Q4 Earnings?

Key Takeaways AbbVie's oncology franchise is projected at $1.75B in Q4 2025 sales, nearly 4% year-over-year growth.ABBV's Venclexta, Epkinly and Elahere likely drove gains, partly offset by declining Imbruvica sales.Investor focus stays on AbbVie's immunology drugs Humira, Rinvoq and Skyrizi ahead of Q4 results.A meaningful portion of AbbVie’s (ABBV) revenues comes from its oncology franchise. Initially anchored by blood cancer drugs Imbruvica and Venclexta, the company has expanded its offerings into solid ...